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Background and purpose: Recovery after stroke occurs on the basis of speciﬁc
molecular events. Genetic polymorphisms associated with impaired neural repair or
plasticity might reduce recovery from stroke and might also account for some of the
intersubject variability in stroke recovery. This study hypothesized that the ApoE 4
polymorphism and the val66met polymorphism for brain-derived neurotrophic factor
(BDNF) are each associated with poorer outcome after stroke. Associations with
mitochondrial genotype were also explored.
Methods: Genotypes were determined in 255 stroke patients who also received
behavioral evaluations in the Glycine Antagonist In Neuroprotection (GAIN) clinical
trials. The primary outcome measure was recovery during the ﬁrst month post-stroke,
as this is the time when neural repair is at a maximum and so when genetic inﬂuences
might have their largest impact. Two secondary outcome measures at 3 months post-
stroke were also examined.
Results: Genotype groups were similar acutely post-stroke. Presence of the ApoE 4
polymorphism was associated with signiﬁcantly poorer recovery over the ﬁrst month
post-stroke (P = 0.023) and with a lower proportion of subjects with minimal or no
disability (modiﬁed Rankin score 0–1, P = 0.01) at 3 months post-stroke. Indeed,
those with this polymorphism were approximately half as likely to achieve minimal or
no disability (18.2%) versus those with polymorphism absent (35.5%). Findings were
conﬁrmed in multivariate models. Results suggested possible eﬀects from the val66met
BDNF polymorphism and from the R0 mitochondrial DNA haplotype.
Conclusions: Genetic factors, particularly the ApoE 4 polymorphism, might con-
tribute to variability in outcomes after stroke.
Spontaneous recovery occurs after a stroke but is highly
variable and generally incomplete. Studies in animals
have provided molecular insights into the basis of this
recovery, indicating that the brain undergoes sponta-
neous repair and remodeling after a stroke. A better
understanding of the molecular events underlying
stroke recovery in humans would be useful to advance
application of restorative therapeutics [3].
Genetic polymorphisms have provided useful insights
at the molecular level in a number of domains of stroke
research, such as pathogenesis [4] and therapy [5]. Al-
though disease-related states can be inﬂuenced by
numerous genes, a single gene can sometimes have
substantial impact, through the consequences of speciﬁc
gene polymorphisms. The current study examined the
inﬂuence on stroke recovery of polymorphisms in two
genes related to neural repair, in a phase III clinical
stroke trial setting. The ﬁrst polymorphism was the
ApoE 4 allele, which is associated with impairment of
some neural repair processes [6,7] as well as increased
neurologic risk in several settings [8–10]. The second
was the val66met brain-derived neurotrophic factor
(BDNF) polymorphism, which is associated with re-
duced activity-dependent BDNF secretion, reductions
in some forms of brain plasticity, and changes in brain
structure and function [11,12].
The main hypothesis tested in the current study was
that the ApoE 4 polymorphism and the BDNF val66-
met polymorphism are each associated with poorer
recovery from stroke. The primary end-point was
recovery over the ﬁrst month post-stroke, when neural
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repair is maximal and thus genetic inﬂuences might be
strongest. Two secondary end-points examined recov-
ery and disability at 3 months after stroke.
An additional exploratory hypothesis was that mito-
chondrial DNA (mtDNA) haplotype also inﬂuences
recovery after stroke. The rate of novel mutations in
mtDNA is 10-fold higher compared to nuclear DNA,
which has resulted in speciﬁc haplotype groups around
the world. Studies suggest that mtDNA haplotype is
associated with a number of clinical conditions such as
degenerative diseases [13] and risk of stroke [14,15], and
is important to the energy metabolism and so potentially
to brain reformatting in the setting of stroke recovery.
Methods
Subjects
This report describes a subset of patients from the
GAIN clinical trials. Sixty-seven of the 305 participat-
ing sites in the GAIN Americas [1] and GAIN Inter-
national [2] trials, representing 17 of the 23 GAIN
enrollment countries, added to the protocol the possi-
bility to oﬀer blood drawing to patients on a voluntary
basis for later genotyping. Of the 3493 patients treated
in the two GAIN studies, 255 (114 from GAIN
Americas and 141 from GAIN International) also
consented to have blood drawn and stored for later
testing in this manner. Note that baseline features of the
current cohort, as versus the overall GAIN trial en-
rollees, were very similar, for example, mean age 69 vs.
70 years, median NIHSS score 11 vs. 12, 18% vs. 15%
with intracerebral hemorrhage, and 21% vs. 25% dia-
betic. As part of the GAIN studies, prior to any
enrollment, personnel at each site were trained to score
the NIH Stroke Scale (NIHSS) and modiﬁed Rankin
Scale (mRS), including certiﬁcation for NIHSS. The
NIHSS was assessed acutely (immediately prior to
treatment, that is, within 6 h of stroke onset) as well as
1 and 3 months post-stroke. Assessments also included
mRS at 3 months post-stroke. Inclusion criteria for
both GAIN trials included treatment started <6 h after
stroke onset, age ‡18 years, limb weakness, and pre-
stroke independence (pre-stroke mRS score £1).
Exclusion criteria included unresponsiveness and rap-
idly improving symptoms. All research was approved
by appropriate Institutional Review Boards.
Genotyping
Blood was aliquoted and stored at )80C, and genomic
DNA was extracted from white blood cells using the
standard DNA isolation technique. The val66met
BDNF polymorphism and ApoE 4 polymorphism, as
well as mitochondrial DNA (mtDNA) haplotype, were
then tested at the University of California, Irvine. A
subject identiﬁer linked stored blood samples with
clinical data, and all samples were de-identiﬁed and
anonymized prior to genotyping so that DNA analyses
could be performed blinded to clinical data.
The presence of the BDNF val66met polymorphism
was determined as described previously [12]. ApoE
genotype was assessed by PCR–RFLP (Restriction
Fragment Length Polymorphism) analysis, as described
elsewhere [16]. Determination of mtDNA haplotype
was carried out by analysis of the hypervariable se-
quences of the non-coding region and by PCR–RFLP
of the mtDNA coding region. Selected RFLP haplotype
markers, deﬁning the major mitochondrial haplo-
groups, were analyzed according to Torroni et al. [17].
Data analysis
The main study hypothesis was that the ApoE 4 and
the BDNF val66met polymorphism, each of which has
been linked with a reduction in certain neural repair or
plasticity events, are each related to poorer outcome
after stroke. Three outcome measures were examined.
The primary outcome measure for the current analyses
was behavioral recovery over the ﬁrst month after
stroke, the time when molecular reformatting of the
brain is at a maximum after stroke [3] and so the
timepoint when genetic factors might have their largest
impact. Recovery was expressed as change in NIHSS
score from acute stroke to 1 month post-stroke. The
two secondary end-points were recovery over the
3 months after stroke, the time when spontaneous
improvement reaches a ﬁnal plateau for most patients,
expressed as change in NIHSS score from acute stroke
to 3 months post-stroke; and the probability of reach-
ing minimal or no disability at 3 months post-stroke,
expressed as the proportion of patients with mRS score
0–1.
Study hypotheses were ﬁrst examined for bivariate
relationships. Most outcome measures were not nor-
mally distributed and could not be transformed to a
normal distribution, and so non-parametric statistical
methods were used for bivariate analyses (Wilcoxon
rank sums testing, Fishers exact, or Chi-square tests, as
appropriate). Because neither GAIN study found a
diﬀerence between placebo and active treatment, these
two arms were combined. Analyses used a < 0.05 and
were two-tailed. The two analyses of the NIHSS score
were corrected for multiple comparisons and thus had
threshold for signiﬁcance of P < 0.025. Ten subjects
died by 1 month, and 10 more by 3 months, during the
study; for these subjects, missing data were imputed by
assigning the poorest value for each scale. Amongst
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subjects with missing scores not attributed to death, last
available values were carried forward. Power calcula-
tions suggested a total of 84 patients needed to obtain
80% power, with 2-sided a < 0.05, to detect a diﬀer-
ence in proportion of subjects with favorable outcome
of 0.28, which is the value reported for ApoE 4 in
relation to proportion of subjects with good outcome
(Glasgow Outcome Scale score = 5) after traumatic
brain injury [8]. The study was therefore not powered to
detect a gene dose eﬀect. Because the number of sub-
jects with two copies of either polymorphism was small
(Table 1), primary analysis therefore excluded any
subjects with two polymorphism copies, although a
secondary analysis was performed that included all
subjects, with polymorphism status treated as present
versus absent. An additional secondary analysis
examined only those subjects with ischaemic stroke.
Study hypotheses were next examined using multi-
variate modeling, which adjusted for confounding
variables and provided further insight into the inde-
pendent relationships between the two genotypes of
interest. A stepwise (P values of 0.25 to enter, 0.1 to
leave) forward nominal logistic model was constructed
for predicting the proportion of subjects with minimal
or no disability at 3 months. For both of the genotypes
of interest, the variable polymorphism present versus
absent was entered into the model, along with nine
covariates: presence of hypertension, presence of dia-
betes mellitus, current smoking status, age, gender,
treatment arm to which randomized, GAIN study into
which subject was enrolled, stroke classiﬁcation (intra-
cerebral hemorrhage versus ischaemic), and baseline
stroke severity (acute NIHSS score).
Additional secondary analyses explored the rela-
tionship between outcomes and mitochondrial haplo-
type. A range of haplogroups was considered, including
from Caucasian (R0, including H and HV, U, and JT),
African (L), and Asian haplogroups (M and N). Based
on mitochondrial phylogeny, mtDNA haplotypes were
clustered into one of six macrohaplogoups (R0, N, U,
L, M, or JT) for statistical analysis. Outcomes were
examined across the six haplotypes, and post hoc tests
examined outcome in relation to each haplotype, the
latter using corrected signiﬁcance threshold of
P < 0.0083.
Results
Genotype distributions
Of the 255 with stored blood, nine subjects had two
copies of the val66met polymorphism, two had
two copies of the ApoE 4 polymorphism, and one had
two copies of both polymorphisms, leaving 241 subjects
for primary analyses (subjects with 0–1 copies of either
polymorphism) and 255 for secondary analyses (all
subjects, that is, 0–2 copies of either polymorphism).
The incidence of these two polymorphisms was not
correlated (P = 0.64), and each was in Hardy–Wein-
berg equilibrium.
Table 1 Baseline characteristics according to BDNF and ApoE genotype
Measure
No. of copies BDNF val66met polymorphism No. of copies ApoE 4 polymorphism
0 1 2 0 1 2
No. of subjects 158 85 12 195 57 3
Age (in years) 69.9 ± 12.5 67.8 ± 12.7 64.3 ± 13.3 69.0 ± 12.8 68.6 ± 12.1 68.5 ± 12.7
Gender 54%M/46%F 58%M/42%F 83%M/17%F 57%M/43% F 54%M/46% F 67%M/33%F
Ethnicity 89%C/5%
A/6% O
73%C/26%
A/1% O
58% C/42%
A/0% O
83%C/14%A/3%O 80%C/14%A/6%O 100%C
Hypertension, % 57 68 67 61 61 67
Diabetes mellitus, % 22 20 25 21 31 33
Hypercholesterolemia, % 20 25 8 18 28 33
Index stroke was
intracerebral
hemorrhage, %
15 24 25 19 18 0
Died by 3 months
post-stroke, %
8 9 0 7 12 0
NIH Stroke Scale
score (acutely)
11.5 10.0 8.0 11.0 12.0 12.0
BDNF, brain-derived neurotrophic factor.
Values for behavioral measures are median; for age, mean ± SD; C = Caucasian, A = Asian, O = Other (Black, Hispanic, Other).
Primary analysis focused on the 241 subjects with 0–1 copies of either polymorphism, amongst whom ethnicity (P < 0.0001) varied according to
BDNF val66met polymorphism status. No baseline measured varied according to ApoE 4 polymorphism status. The same was true in a secondary
analysis that examined all 255 subjects for presence or absence of each polymorphism.
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Baseline data
Genotype groups had overall similar characteristics at
baseline (Table 1). Amongst the 241 subjects with 0–1
copies of either polymorphism, ethnicity (P < 0.0001)
varied according to whether the val66met BDNF poly-
morphism was present or absent (a higher proportion
of Asian subjects had the val66met BDNF polymor-
phism, as expected [18]), and no measure varied
according to ApoE 4 status. The same was true when
baseline data were examined for the 197 of these pa-
tients with ischaemic stroke. This was also true when all
255 subjects were analyzed.
Genotype and recovery over the first month after stroke
Bivariate analysis of the primary end-point, change in
NIHSS score from acute to 1 month after stroke
amongst the 241 subjects with 0–1 copies of either
polymorphism, found that presence of the ApoE 4
polymorphism was associated with poorer recovery
(P = 0.023, Table 2): subjects with this polymorphism
(n = 55) had a median change in NIHSS score of only
4 points [interquartile range (IQR) 0–5], compared to 5
points [IQR 2–8] amongst those lacking the polymor-
phism (n = 186). Similar results were suggested for the
presence of the BDNF val66met polymorphism
(P = 0.036), where those with the polymorphism
(n = 83) had a median change in NIHSS score of only
4 points [IQR 1–6], compared to 5 points [IQR 2–8]
amongst those lacking this polymorphism (n = 158).
When the 197 patients with ischaemic stroke were
analyzed for the presence or absence of each polymor-
phism (Table 3), the ApoE 4 polymorphism remained
associated with poorer recovery over the ﬁrst month
(P = 0.047). Results from a secondary analysis that
included all 255 subjects did not reach signiﬁcance for
either genotype.
Genotype and outcomes at 3 months after stroke
Bivariate analysis was also performed on the two sec-
ondary end-points. The ﬁrst of these was mRS score of
0–1 at 3 months after stroke, which indicates minimal
or no disability. Amongst the 241 subjects with 0–1
copies of either polymorphism, presence of ApoE 4
polymorphism was associated with a signiﬁcantly
(P = 0.01) lower proportion of patients achieving mRS
score of 0–1 at 3 months after stroke [18.2% (10/55
patients) when polymorphism present; 35.5% (66/186
patients) when polymorphism absent; see Table 2 and
Fig. 1a]. Presence of the ApoE 4 polymorphism thus
nearly doubled the risk of having signiﬁcant disability
at 3 months post-stroke. This too was conﬁrmed in
the 197 patients with ischaemic stroke (P = 0.018,
Table 3), where a lower proportion of those with
the ApoE 4 polymorphism present had mRS score of
0–1 at 3 months compared to those with this poly-
morphism absent [19.6% (9/46 patients) when poly-
morphism present; 37.8% (57/151 patients) when
Table 2 Outcome measures according to BDNF and ApoE genotype for all patients
Measure
No. of copies BDNF val66met polymorphism No. of copies ApoE 4 polymorphism
0 1 2 0 1 2
No. of subjects 158 85 12 195 57 3
Recovery over the ﬁrst
month (change in NIHSS
score from acute to 1 month
after stroke)
)5 ()1.75 to )8) )4 ()1 to )6) )6.5 ()0.5 to )8) )5 ()1 to )8) )4 (0 to )6) )6 ()4 to )10)
Recovery over the ﬁrst
3 months (change in NIHSS
score from acute to 3 months
after stroke)
)6 ()2 to )10) )5 ()1.5 to )7.5) )6.5 ()1.5 to )8.75) )6 ()2 to )9) )5 (0 to )8) )9 ()8 to )10)
Minimal or no disability
at 3 months (proportion of
subjects with mRS score of
0–1 at 3 months)
51 (32%) 25 (29%) 8 (67%) 71 (36%) 12 (21%) 1 (33%)
BDNF, brain-derived neurotrophic factor.
Primary analysis focussed on the 241 subjects with 0–1 copies of either polymorphism and found that recovery over the ﬁrst month was poorer
when either the ApoE 4 (P = 0.023) or BDNF val66met (P = 0.036) polymorphism was present, and that the proportion of subjects with minimal
or no disability at 3 months was lower (P = 0.01) amongst those in whom the ApoE 4 polymorphism was present. A secondary analysis of all 255
subjects found that presence of ApoE 4 was associated with a lower proportion of subjects with minimal or no disability at 3 months as compared
to subjects in whom this polymorphism was absent (P = 0.029), but that presence or absence of the BDNF val66met polymorphism was not related
to any of the three outcomes. There was no interaction of any of these results with gender. Note that a negative value for NIHSS score change
indicates clinical improvement. NIHSS values are median (IQR); mRS values, number of subjects (percent genotype).
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polymorphism absent]. Secondary analysis of all 255
subjects was also consistent (P = 0.029), ﬁnding that
the proportion of subjects with mRS score of 0–1 at
3 months remained lower in those with the ApoE 4
polymorphism present, compared to those with poly-
morphism absent [21.7% (13/60 patients) when poly-
morphism present; 36.4% (71/195 patients) when
polymorphism absent, see Fig. 1b]. The proportion of
subjects with minimal or no disability at 3 months did
not vary according to the presence versus absence of the
val66met BDNF polymorphism amongst the 241 sub-
jects with 0–1 copies of either polymorphism, amongst
the 197 patients with ischaemic stroke, or amongst all
255 patients. Regarding the other secondary end-point,
change in NIHSS score from acute stroke to 3 months,
none of the analyses found a signiﬁcant association
with either polymorphism.
Predictive model
A model directly compared ApoE 4 status and BDNF
val66met polymorphism status whilst controlling for
nine baseline and demographic measures. The outcome
measure used for this model was the proportion of pa-
tients with mRS score of 0–1 at 3 months post-stroke. In
primary analysis that focused on the 241 subjects with 0–
1 copies of either polymorphism, two variables survived
as signiﬁcant predictors, ApoE 4 status (P = 0.006,
odds ratio for ApE4 present, 0.31, 95% CI = 0.12–
0.73) and baseline stroke severity (P < 0.0001, odds
ratio per point in NIHSS, 0.78, 95% CI = 0.71–0.84).
Note that r2 for this model was 0.26, higher than the r2
value of 0.21 found with the nine covariates alone
without any genetics data. Results were virtually
Table 3 Outcome measures according to BDNF and ApoE genotype for patients with ischaemic stroke
Measure
No. of copies BDNF val66met polymorphism No. of copies ApoE 4 polymorphism
0 1 2 0 1 2
No. of subjects 134 65 9 158 47 3
Recovery over the ﬁrst
month (change in NIHSS
score from acute to 1 month
after stroke)
)5 ()1 to )8) )4 ()1 to )6) )7 ()2 to )9) )5 ()1 to )7) )4 (0 to )6) )6 ()4 to )10)
Recovery over the ﬁrst
3 months (change in NIHSS
score from acute to 3 months
after stroke)
)6 ()2 to )9) )5 ()1.5 to )7.5) )7 ()3 to )9) )6 ()2 to )9) )5 (0 to )8) )9 ()8 to )10)
Minimal or no disability at
3 months (proportion of
subjects with mRS score
of 0–1 at 3 months)
46 (34%) 20 (31%) 6 (67%) 61 (39%) 10 (21%) 1 (33%)
BDNF, brain-derived neurotrophic factor.
Primary analysis focussed on the 197 subjects with ischaemic stroke who had 0–1 copies of either polymorphism and found that recovery over the
ﬁrst month (P = 0.047) and the proportion of subjects with minimal or no disability at 3 months (P = 0.018) each varied according to ApoE 4
status. A secondary analysis of all 208 subjects with ischaemic stroke found that presence of ApoE 4 was associated with a lower proportion of
subjects with minimal or no disability at 3 months as compared to subjects in whom this polymorphism was absent (P = 0.025). Note that for
none of the three outcome measures did results differ according to whether the stroke was ischaemic or hemorrhagic. A negative value for NIHSS
score change indicates clinical improvement. NIHSS values are median (IQR); mRS values, number of subjects (percent genotype).
(a) (b)
Figure 1 ApoE 4 is associated with higher risk of disability after
stroke. (a) In primary analysis of the 241 subjects with 0–1 poly-
morphism copies, the proportion of subjects with minimal or no
disability (mRS score 0–1) 3 months post-stroke varied signiﬁ-
cantly (P = 0.01) in relation to ApoE 4 status (absolute risk
reduction for minimal or no disability with ApoE 4 polymor-
phism present = 17.3%). (b) This remained true for a secondary
analysis that included all 255 subjects for polymorphism presence
versus absence (absolute risk reduction for ApoE 4 absent,
14.7%, P = 0.029). *P < 0.03. Note that in neither case did the
proportion of subjects with minimal or no disability 3 months
post-stroke vary with brain-derived neurotrophic factor val66met
polymorphism status.
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identical when only the 197 patients with ischaemic
stroke were examined in this model. Results were also
near identical in a secondary analysis that included all
255 subjects, where ApoE 4 status (P = 0.026, odds
ratio for ApoE4 present, 0.42, 95%CI= 0.18–0.90) and
baseline stroke severity (P < 0.0001, odds ratio per
point in NIHSS, 0.79, 95% CI = 0.73–0.84) again re-
mained as the signiﬁcant predictors.
Mitochondrial DNA haplotype and stroke outcome
The mtDNA haplogroup could be determined in 227
subjects, as insuﬃcient DNA was available to identify
the haplotype in 14 cases, and were U (14.9%), R0
(42.3%), N (13.3%), M (2.5%), L (4.6%), and JT
(16.6%). The mtDNA haplogroup was not related to
ApoE 4 status (P = 0.18), but was signiﬁcantly related
to the presence of the BDNF val66met polymorphism
(P = 0.0004). The latter was attributed to subjects
carrying the BDNF val66met polymorphism having a
higher frequency of mtDNA haplotypes M and N, as
expected, as both are more common in Asian popula-
tions [18,19]. Two measures varied at baseline in rela-
tion to mtDNA haplogroup: ethnicity, as expected
(P < 0.0001; JT, R0, and U were 99–100% Caucasian;
M and N were mainly Asian) [19], and the proportion
of subjects whose stroke was intracerebral hemorrhage
(P = 0.037), being highest in M and N haplotypes.
Across the six mtDNA haplotypes, no signiﬁcant rela-
tionship was found for stroke recovery or minimal
disability end-points. Exploratory post hoc analysis
examining each haplotype separately suggested an eﬀect
in one case: subjects with the R0 haplotype had a
median 5 point [IQR 3–9] change in NIHSS score from
acute to 1 month post-stroke, compared to a 4 point
[IQR 0–6] change in non-R0 (P = 0.004).
Discussion
This study suggested that genetic polymorphisms may
be related to diﬀerences in outcome after stroke, inde-
pendent of baseline deﬁcits. The results were strongest
for patients carrying the ApoE 4 polymorphism. Ge-
netic variability may account for some of the inter-
subject variability in stroke recovery and might be a
source of molecular insights into stroke outcomes in
humans.
ApoE is the most abundant brain lipoprotein, and its
ApoE 4 polymorphism adversely aﬀects processes re-
lated to repair and recovery such as neuronal remod-
eling [6] and synaptic turnover [7]. Consistent with this,
the current analysis found that presence of the ApoE 4
polymorphism was associated with poorer recovery
during the time of maximum remodeling, from acute
presentation to 1 month after stroke. The magnitude
was modest but could be important to some patients.
ApoE 4 was also associated with an absolute risk
reduction of 17.3% for achieving minimal or no dis-
ability at 3 months post-stroke (Fig. 1a), a ﬁnding that
is substantial given that absolute risk reduction with
administration of IV tPA for the same end-point (mRS
0–1) ranges from 7.3% [20] to 13% [21]. The ApoE 4
polymorphism results remained signiﬁcant when only
patients with ischaemic stroke were assessed and when
patients with two polymorphism copies were examined
in secondary analyses.
ApoE 4 has previously been associated with poorer
outcome after traumatic brain injury [8] or hemorrhagic
stroke [9,10,22], but this association has not been found
in prior studies that examined patients with ischaemic
stroke. There are several possible reasons for the dis-
parity between prior reports and the current ﬁndings.
First, unlike most prior studies, outcomes in the current
study were highly standardized, being performed by
trained examiners in a phase III trial setting. Second,
the inﬂuence of the ApoE 4 polymorphism after stroke
might interact with gender [23], with results varying
according to the population under study; however, this
interaction was not found in the current study (Ta-
ble 2). Third, many prior studies focused on measuring
the proportion of subjects with a poor outcome (death
or dependency) [22] rather than with a good outcome as
in the current analysis. Consistent with this, when
current results were re-examined looking at proportion
of subjects reaching mRS score of 4–6 (death or
dependency) at 3 months, no diﬀerence was seen in
relation to ApoE 4 status. A notable exception [24]
examined ApoE 4 status in relation to minimal or no
disability in the setting of a Phase III clinical trial that
enrolled patients with stroke of <3 h duration at US
sites and did not ﬁnd an association of ApoE 4 status
with outcome. The reasons for discrepancy with current
ﬁndings are unclear but might include diﬀerences in the
entry criteria and in the populations under study, for
example, the GAIN studies excluded patients who were
unresponsive but the prior study [24] did not.
The current study also suggested the possibility that
genetic variations in BDNF and in mitochondrial DNA
might be related to stroke outcome. BDNF is the most
abundant neurotrophin in the brain, has increased
brain levels after stroke, and aﬀects neuronal survival,
diﬀerentiation, and use-dependent plasticity. The
BDNF val66met polymorphism is associated with im-
paired activity-dependent BDNF release, which is tied
to many forms of learning and plasticity. This study
suggested a possible relationship between the presence
of the BDNF val66met polymorphism and poorer
recovery from acute to 1 month after stroke, the period
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of maximum repair and clinical recovery [3]. Although
this P value (0.036) did not survive correction for
multiple comparisons, this ﬁnding is consistent with a
prior study [25] that found that outcome after sub-
arachnoid hemorrhage is poorer in the presence of the
BDNF val66met polymorphism, although interestingly
this association might be most pronounced in those
patients with subarachnoid hemorrhage who have no
associated cerebral infarct [26]. The current results also
suggested a potential relationship between the R0
mtDNA haplotype and outcome after stroke. Mito-
chondria generate cellular energy as well as reactive
oxygen species [27], and so mtDNA has a very high
mutation rate, and has been divided on this basis into
several haplogroups. The current study hypothesized
that mtDNA haplotype might be related to outcome
after stroke, as cellular energetics might be important to
recovery, and indeed some mitochondrial haplogroups
have shown signiﬁcant clinical associations such as with
longevity [28], degenerative disease risk [13], and stroke
risk [14,15]. Although both the BDNF val66met poly-
morphism and the R0 mtDNA haplotype ﬁndings
might reﬂect type I error, current results do suggest
avenues for future research.
Strengths of this study include measurement of
within-subject change beginning with the acute pre-
sentation for the measure of recovery and collection of
outcome measures by trained examiners in a phase III
clinical trial setting. Collection of data across multiple
sites and countries, whilst potentially resulting in
underestimation of associations, increases conﬁdence in
the results and their generalization. Recruitment of
subjects within hours of stroke avoids a selection bias
that might aﬀect studies enrolling late after stroke,
where the sickest patients might not be enrolled because
of early death. Weaknesses include other possible
sources of bias, such as the clinical trials inclusion
criteria and obtaining DNA from only a subset of the
entire cohort of patients treated in the GAIN studies,
although, as mentioned previously, baseline features of
the current group were similar to the overall GAIN
study cohort. Sample size was small by genetic study
standards. For example, the study was not powered to
detect a gene dose eﬀect, and indeed there were very few
subjects with two copies of either polymorphism. For
this reason, it is unclear whether having two copies of
either polymorphism is truly protective, as might be
inferred from Table 2, or whether this is simply because
of chance. The GAIN studies excluded patients who
were unresponsive or had rapidly improving symptoms,
and so the mildest and the worst strokes may been ex-
cluded from the current analyses; as mentioned previ-
ously, such diﬀerences in entry criteria might contribute
to inconsistencies between the current and prior studies
[24] regarding ApoE 4 polymorphism eﬀects. Also, no
data were available on the rehabilitation therapy sub-
jects received during recovery, a covariate of interest to
any study of recovery, although variability in rehabili-
tation might be expected to dilute rather than overes-
timate polymorphism eﬀects. Finally, although the
molecules examined are involved with repair, the cur-
rent data do not rule out that that the BDNF val66met
polymorphism and the ApoE 4 polymorphism inﬂu-
ence outcomes via other mechanisms such as secondary
stroke complications, cognitive eﬀects, or response to
preventative medicines.
The current ﬁndings build on prior studies that sug-
gest that genetic variation can inﬂuence clinical course
after stroke independent of initial injury. These ﬁndings
might be of value to stroke therapy trials, for example,
informing entry criteria and stratiﬁcation, and might
suggest future avenues for individualized medical
treatment after stroke.
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